Literature DB >> 21735521

Retroperitoneal hemorrhage after percutaneous coronary intervention in the current practice era: clinical outcomes and prognostic value of abdominal/pelvic computed tomography.

Gabriel Maluenda1, Lavinia Mitulescu, Itsik Ben-Dor, Michael A Gaglia, Gaby Weissman, Rebecca Torguson, Lowell F Satler, Augusto D Pichard, Nelson L Bernardo, Ron Waksman.   

Abstract

BACKGROUND: Retroperitoneal hemorrhage (RPH) is a serious but infrequent complication of percutaneous coronary intervention (PCI). This study aimed to describe the clinical outcomes of patients who developed RPH following PCI in the current practice era, with particular focus on treatment strategies and the related prognostic value of abdominal/pelvic computed tomography (CT).
METHODS: Among 20,904 patients undergoing PCI, we identified 93 RPH (0.45%) confirmed by CT or by unequivocal surgical findings. We identified three groups with RPH for comparison: patients who developed refractory shock (systolic blood pressure <80 mm Hg for ≥30 min despite fluids and vasopressors, n = 16 [17.2%]); patients with transient hypotension (<30 min, n = 34 [36.6%]); and patients without hypotension (n = 43 [46.2%]). The primary endpoint was a composite of in-hospital mortality, myocardial infarction, and cerebral vascular accident (CVA).
RESULTS: Baseline clinical, angiographic, and procedural characteristics were similar among the three groups. Patients who developed refractory shock had significantly more bleeding quantified by abdominal/pelvic CT (P < 0.001), had a higher rate and amount of red blood cell transfusion (P < 0.001), and were managed invasively more frequently (68.7%) than the rest of the population. The primary endpoint trended higher in patients presenting with refractory shock; however, this difference was not statistically significant. The volume of bleeding quantified by CT and the timing of imaging diagnosis did not correlate with the primary endpoint. Red blood cell transfusion, but not clopidogrel discontinuation, was associated with the primary endpoint.
CONCLUSIONS: RPH remains as a serious complication of PCI and is associated with high rates of mortality and morbidity independently of the therapeutic strategy. In patients who were hemodynamically stable, RPH volume as quantified by non-contrast abdominal/pelvic CT did not contribute to prognosis.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21735521     DOI: 10.1002/ccd.23200

Source DB:  PubMed          Journal:  Catheter Cardiovasc Interv        ISSN: 1522-1946            Impact factor:   2.692


  4 in total

1.  Medicolegal implications of radial and femoral access for coronary angiography and intervention in 2016: Focus on retroperitoneal hemorrhage.

Authors:  Konstantinos V Voudris; Mladen I Vidovich
Journal:  J Transl Int Med       Date:  2016-04-14

2.  Incidence and impact on prognosis of bleeding during percutaneous coronary interventions in patients with chronic kidney disease.

Authors:  Gjin Ndrepepa; Franz-Josef Neumann; Salvatore Cassese; Massimiliano Fusaro; Ilka Ott; Stefanie Schulz; Petra Hoppmann; Gert Richardt; Karl-Ludwig Laugwitz; Heribert Schunkert; Adnan Kastrati
Journal:  Clin Res Cardiol       Date:  2013-10-04       Impact factor: 5.460

3.  Angiotensin type 1 receptor A1166C gene polymorphism is associated with endothelial dysfunction and in-stent restenosis after percutaneous coronary intervention.

Authors:  Yu Li; Fang Chen; Xiaoling Zhang; Yuechun Gao; Changyan Wu; Haiyan Li; Yuchen Zhang
Journal:  Int J Clin Exp Pathol       Date:  2015-06-01

4.  A prospective, randomized comparison of promus everolimus-eluting and TAXUS Liberte paclitaxel-eluting stent systems in patients with coronary artery disease eligible for percutaneous coronary intervention: the PROMISE study.

Authors:  Ung Kim; Chan-Hee Lee; Jung-Hwan Jo; Hyun-Wook Lee; Yoon-Jung Choi; Jang-Won Son; Sang-Hee Lee; Jong-Seon Park; Dong-Gu Shin; Young-Jo Kim; Myung-Ho Jeong; Myung-Chan Cho; Jang-Ho Bae; Jae-Hwan Lee; Tae-Soo Kang; Kyung-Tae Jung; Kyung-Ho Jung; Seung-Wook Lee; Jang-Hyun Cho; Won Kim; Seung-Ho Hur; Ki-Sik Kim; Heon-Sik Park; Moo-Hyun Kim; Jin-Yong Hwang; Doo-Il Kim; Tae-Ik Kim
Journal:  J Korean Med Sci       Date:  2013-10-31       Impact factor: 2.153

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.